COVID-19 Vasculitis and vasculopathy—Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells

Sami Giryes1 · Nicola Luigi Bragazzi1 · Charles Bridgewood1 · Gabriele De Marco1 · Dennis McGonagle1,2

Received: 20 January 2022 / Accepted: 25 February 2022 / Published online: 12 April 2022
© The Author(s) 2022

Abstract
The SARS-CoV-2 virus ACE-2 receptor utilization for cellular entry and the defined ACE-2 receptor role in cardiovascular medicine hinted at dysregulated endothelial function or even direct viral endotheliitis as the key driver of severe COVID-19 vascular immunopathology including reports of vasculitis. In this article, we critically review COVID-19 immunopathology from the vasculitis perspective and highlight the non-infectious nature of vascular endothelial involvement in severe COVID-19. Whilst COVID-19 lung disease pathological changes included juxta-capillary and vascular macrophage and lymphocytic infiltration typical of vasculitis, we review the evidence reflecting that such “vasculitis” reflects an extension of pneumonia inflammatory pathology to encompass these thin-walled vessels. Definitive, extrapulmonary clinically discernible vasculitis including cutaneous and cardiac vasculitis also emerged—namely a dysregulated interferon expression or “COVID toes” and an ill-defined systemic Kawasaki-like disease. These two latter genuine vasculitis pathologies were not associated with severe COVID-19 pneumonia. This was distinct from cutaneous vasculitis in severe COVID-19 that demonstrated pauci-immune infiltrates and prominent immunothrombosis that appears to represent a novel immunothrombotic vasculitis mimic contributed to by RNAaemia or potentially diffuse pulmonary venous tree thrombosis with systemic embolization with small arteriolar territory occlusion, although the latter remains unproven. Herein, we also performed a systematic literature review of COVID-19 vasculitis and reports of post-SARS-CoV-2 vaccination related vasculitis with respect to the commonly classified pre-COVID vasculitis groupings. Across the vasculitis spectrum, we noted that Goodpasture’s syndrome was rarely linked to natural SARS-CoV-2 infection but not vaccines. Both the genuine vasculitis in the COVID-19 era and the proposed vasculitis mimic should advance the understanding of both pulmonary and systemic vascular immunopathology.

Keywords SARS-CoV-2 · COVID-19 Vaccine · Vasculitis · Vasculopathy · Endotheliitis · Immunothrombosis

Introduction—The Scope of SARS-CoV-2 Related Vascular Pathology

The novel highly transmissible SARS-CoV-2 virus resulted in fatal pneumonia in a subset of patients and quickly garnered great interest in the cardiovascular and rheumatology arenas, because of the prominent vascular immunopathology. The most striking pathological feature was extensive viral alveolitis but also vascular thrombosis and reports of vascular wall inflammation [1, 2]. Compelling evidence for extrapulmonary vasculitis and vasculitis mimics also emerged during the COVID-19 pandemic which are described in in this article. We also review the extant literature by performing a systematic literature review up until September 2021 that has reported genuine vasculitis in SARS-CoV-2 infection, and we also review post-COVID-19
vaccinations for an emergent vasculitis signal given that most available SARS-CoV-2 vaccines are directed to the spike protein which engages the ACE2 receptor that is known to be expressed on endothelial cells[3]. We also cover the totality of systemic vascular complications—whether vasculopathy, vasculitis or vasculitis mimics and describe how these appear to be independent of productive infection of vascular endothelial cells. We will also focus on extrapulmonary vascular pathology including genuine autoimmune vasculitis (referred also as true, bespoke, or bona fide vasculitis in this text) and a novel potential vasculitis mimic related to diffuse immunothrombosis outside the pulmonary territory that has been reported in SARS-CoV-2.

ACE2 Centric Vasculopathy model including vascular infection

The SARS-CoV-2 virus employs the ACE2 receptor for cellular entry with this receptor having a widespread upper and lower respiratory tract distribution from nasal epithelium to the alveoli, most notably alveolar type 2 pneumocytes[4, 5] but the ACE2 receptor also has a well-established role in the cardiovascular system[6, 7]. Also, the comparatively minuscule SARS epidemic at the turn of the millennium had already provided substantial information about this related structurally close beta-coronavirus that also used the ACE2 receptor[4]. Beyond the lower respiratory tract symptoms of COVID-19 pneumonia explained by ACE2 receptor expression, upper respiratory tract symptoms of anosmia and pharyngitis could also be linked to high local ACE2 receptor expression levels[8]. Prior data also showed ACE-2 receptor expression on other cell types including endothelial cells and cardiomyocytes[4, 9] and provided potential pointers to the novel emergent cardiovascular pathology in the initial COVID-19 wave. Independently, of these observations in SARS, the role of ACE2 receptor as a regulator of cardiovascular system including hypertension, myocardial injury, obesity and diabetes was reported in several models systems, but to variable extents[10, 11]. Cardiac enzyme elevations and lung and systemic vasculopathy quickly cemented the notion that ACE-2 dysfunction in the cardiovascular system was a key mortality driver in emergent COVID-19 pneumonia and associated vascular pathology[12, 13]. Accordingly, early in the pandemic, there was great interest in the influence of cardiovascular drugs that modulated ACE2 expression including Renin–Angiotensin inhibitors, nonsteroidal anti-inflammatory, and many others[3, 14–16].

The prior SARS epidemic was associated with both pulmonary capillary and larger vessel thrombosis and also reports of viral myocarditis and in common with SARS-CoV-2, the SARS virus also utilized the ACE2 receptor[17–19]. Given that recombinant ACE-2 mitigates against experimental pneumocyte injury, and since SARS-CoV-2 spike protein can downregulate ACE-2[20], it has been considered that SARS-CoV-2 derived spike protein without actual infection might trigger endothelial cell dysregulation and immune activation[21]. A third beta coronavirus termed Middle East respiratory syndrome coronavirus (MERS-CoV) has been another twenty-first century emergent coronavirus and limited pathological literature supports the idea of an identical immunopathology with pneumonia and reported immunothrombosis and an increased mortality in subjects with cardiovascular risk factors[22–24]. As this latter virus shows an identical immunopathology but does not target the ACE2 receptor[23, 25] and recent studies showing low or even absent endothelial cells ACE2 expression[26–28], then it is likely that novel beta coronaviruses are capable of mediating immunopathology, including vasculitis, independently of the ACE-2 receptor and that factors extrinsic to ACE-2 appear to be critical to COVID-19 related vasculopathy, which is the focus of this paper.

Histological Reports of Pulmonary Vasculitis in COVID-19 and what it means

Pathology from the primary lung target organ in COVID-19 have consistently shown that viral alveolitis is accompanied by peri-capillary myeloid and lymphoid cell infiltration[29, 30]. Pulmonary capillary, pulmonary arteriolar and pulmonary venular vessel wall inflammation has been associated with extensive and pervasive vascular luminal thrombosis[2, 31]. Initially, it was considered that endothelial inflammation due to direct viral infection or “viral endotheliitis” accounted for the immunothrombosis[29, 32]. However, it has since emerged that endothelial cells have comparatively low ACE2 expression and are also fairly resistant to productive viral infection supporting the concept that a “genuine vasculitis” rather than active infection, may thus account for the SARS-CoV-2 vascular pathology (Fig. 1)[26–28]. Indeed, it has likewise emerged that direct endothelial infection with productive SARS-CoV-2 viral replication does not occur in humans[27, 33, 34]. Also, in the prior SARS outbreak, reports of direct endothelial infection were never conclusively shown[35, 36].

Pathological pulmonary changes described as vasculitis have been reported in COVID-19 pneumonia. In one study, around a quarter of subjects had perivascular lymphocyte cuffing or capping, that was described as compatible with vasculitis[31]. In another postmortem study, 4 of 11 cases had predominant macrophage infiltration into the pulmonary arterial wall, and also CD4, CD8 T-cells and B cells were reported, with these histological features being designated as arteritis[37]. One more pathological report described an endarteritis obliterans in conjunction with C5-9 complement...
pathway activation at the site of vasculitic change[38]. However, the pervasive impact of severe alveolitis with associated inflammation in the juxta-capillary and thin-walled pulmonary vascular system may account for the extensive lung vascular pathology (Fig. 2). We suspect that studies demonstrating juxta-capillary lymphocytic infiltration that have been attributed to a “viral endotheliitis” may reflect lymphocyte migration or infiltration either to or from the closely juxtaposed pneumonic alveolar territory (Fig. 2) [1, 29, 39]. Rather than representing a primary pulmonary vasculitis in the later phases where the SARS-CoV-2 virus is cleared, such microscopic “vasculitis” may be part of the so-called Virchow’s triad where a severe extra-vascular alveolitis leading to vascular wall inflammation is linked to vessel wall immune cell infiltration and luminal thrombosis (Fig. 2).

Severe alveolar centric inflammation without actual endothelial infection likely leads to extensive immunothrombosis by a myriad of mechanisms including pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) related endothelial activation[40, 41]. Factors including tissue factor released by activated immune cells in the lungs or systemically also likely trigger coagulation[40]. Viral RNA access to the capillary lumen consequent to damage of the sub-micrometer alveolar–capillary barrier may also contribute to Factor XII and X activation with local coagulation cascade activation [42–44]. Presently, the understanding of the COVID-19 lung vascular immunopathology is conceptualized in terms of severe immunothrombosis that constrains SARS-CoV-2 to the alveolar territory[45, 46]. The severity and magnitude of the alveolar centric inflammation leads to profound endothelial cell damage and even endothelial cell death captured under the umbrella term of endothelialopathy[47, 48].

What Did We Know Before The COVID-19 Era About Infection and Vasculitis?

The question of vasculitis as a manifestation of infection disease is not a unique to COVID-19 and was well described phenomenon with the oldest pathogens known for humankind such as syphilis and tuberculosis. In most of the cases, this infectious vasculitis is a consequence of direct invasion, extension of localized focus or septic embolization of bacterial, viral, fungal, or parasitic infections to the endothelial cells and vascular wall which is usually accompanied by intense inflammatory response to the vessel wall and other symptoms.
related to the main infection and rarely confused with bona fide vasculitis [49, 50]. For example, in syphilis, treponema pallidum invasion of endothelial cells and endothelial barriers such retina, placenta, and blood–brain barrier is believed to be one of the main bacteria virulence factors; hence direct syphilis infection may cause different vasculitic syndromes from central nervous system vasculitis, retinal vasculitis and aortitis [51–53]. Other pathogens have been studied as a possible mechanistic triggers in the development of bona fide vasculitis, such as staphylococcus aureus in ANCA associated vasculitis and streptococcal infection in Henoch–Schonlein purpura (HSP), but the causality in these cases is still controversial [54, 55]. Only for a few pathogens has causality been established, such as Hepatitis C Virus (HCV) related cryoglobulinemic vasculitis, which is mediated mainly by the binding of HCV viral particles to IgM with rheumatoid factor activity resulting in the production of cold-precipitable immune complexes, which binds to endothelial cells activating the complement system and inflammatory response [56–58].

Vaccinations including influenza vaccine, hepatitis B, Bacille Calmette-Guerin (BCG), and human papillomavirus vaccines, all of which lack live microbes with the exception of BCG, have been associated with occasional vasculitis development [59]. The commonest patterns of vasculitis from the same study were HSP and Kawasaki disease. As most of these vaccines do not contain viable replicating pathogens, these findings suggest a non-specific activation of immunity in susceptible individuals that results in vasculitis.

**COVID-19 Pulmonary Pathology versus Behcet’s Pulmonary Vasculitis**

It is useful to compare the COVID-19 pulmonary vasculopathy with the genuine pulmonary vasculitis in Behcet’s Disease (BD) that is usually characterized by an absence of interstitial pathology but pulmonary vascular wall...
inflammation with neutrophilic inflammation and aneurysmal dilatation[60]. The BD vascular centric inflammation is associated with both superficial and deep immunothrombosis and neutrophilic inflammation[60, 61]. Likewise, neutrophils play a key role in the immunothrombosis associated with COVID-19 with netotic material, platelets and other immune cells forming a key part of the clot in COVID-19 disease [62, 63]. Moreover, in critical COVID-19 patients there is evidence of extensive immune cell activation in the peripheral blood that also includes neutrophils[64].

An interesting facet pointing to shared features between BD and COVID-19 pulmonary vascular involvement is anti-coagulation inefficacy in BD immunothrombosis and likewise in critical COVID-19 pneumonia where full dose anti-coagulation has no benefit and may be potentially detrimental[65]. Therapeutically, corticosteroids may be beneficial in deep venous thrombosis (DVT) and other severe manifestations of BD as in severe COVID-19 patients [66]. Although an element of pulmonary haemorrhage is a historical feature of severe COVID-19, this may be dysregulation perfusion rather than the aneurysmal rupture as seen in BD. In keeping with the fact that the genuine vasculitis associated with BD is completely distinct from the COVID-19 immunopathology is the limited data suggesting exacerbation of BD related vascular pathology being linked to COVID-19 infection or vasculitis. In one report, of ten patients with BD during COVID-19 infection, one patient with long-standing BD and central nervous system involvement reported having a DVT, which was unusual to his BD course and responded to steroids without anticoagulation [67]. We have noted occasional BD flares following SARS-CoV-2 vaccination, but these were restricted to mucocutaneous disease and arthritis[68].

**Bona Fide Vasculitis in COVID-19**

We performed two separate systemic literature reviews of COVID-19 related vasculitis using the following search engines; PubMed/MEDLINE, Scopus, Google Scholar and Embase. The searches were conducted to include articles until September 2021. In the first search, we looked for reported cases of vasculitis after SARS-CoV-2 infection and the second after COVID-19 vaccination. We used this strategy as we reasoned that systemic infection with severe lung damage may predispose to vasculitis compared to the controlled inoculum strategies of vaccination, where the lung tissue is spared severe damage.

For this purpose, we used the following search string in the first search: (SARS-CoV-2 OR COVID-19 OR "novel Coronavirus" OR "emerging Coronavirus") AND (vasculitis OR "Giant cell arteritis" OR Takayasu OR “large-vessel vasculitis” OR Cogan OR “Polyarteritis nodosa” OR Buerger OR "ANCA-associated vasculitis" OR (“antineutrophil cytoplasmic antibodies” AND vasculitis) OR Wegener OR polyangiitis OR Churg-Strauss OR "Urticarial vasculitis” OR Goodpasture OR “anti-glomerular basement membrane disease” OR “cutaneous small-vessel vasculitis” OR “cutaneous vasculitis” OR “IgA vasculitis” OR “leukocytoclastic vasculitis” OR “Henoch-Schönlein Purpura”).

For the second search strategy in SARS-CoV-2 vaccinated subjects, we used the same search string, but we added the vaccine-related component: (vaccine OR vaccination OR immunisation OR immunization). Medical subheadings (MeSH) terms and wild card truncated words option were used when necessary.

Clinical case reports and case series providing sufficient details were included (for instance, case reports/case series reporting only clinical illustrations/image were excluded). Reports of vasculitis like features including thrombosis and associated complement activation within vessels were not defined as vasculitis but considered as immunothrombotic vasculitis mimics and were not included in the vasculitis groups. Articles were excluded if the vasculitis could be linked to a drug, rather than directly to the SARS-CoV-2 infection or vaccination or if the vasculitis relapsed and not newly diagnosed. Epidemiological surveys computing incidence/prevalence rates but not providing sufficient clinical details were not retained in the analysis. Extensive cross-referencing was applied, to ensure the maximum coverage and to increase the chance of including all relevant articles. Already existing reviews (in particular, systematic reviews) were scanned to include already abstracted data and eventually update them. We did not search for “COVID toes” or Kawasaki Disease (KD) that is linked to Multisystem Inflammatory Syndrome (MIS). Our focus was on previously known systemic vasculitides rather than the two recently defined vasculitis entities.

**Vasculitis in SARS-CoV-2 Infection**

Excluding Kawasaki disease like vasculitis associated with the MIS spectrum and “COVID toes”, only forty-eight vasculitis cases were described (Table 1) [69–94]. These are described starting with large vessel vasculitis.

**Large Vessel Vasculitis** There have been occasional reports of large vessel vasculitis including central nervous system vasculitis occurring with severe COVID-19 where imaging demonstrated a pattern resembling GCA, but these were uncommon[91, 92, 95]. We found no cases of Takayasu’s vasculitis following COVID-19.

**Medium and Small Vessel Vasculitis- ANCA associated vasculitis** The diagnosis of new ANCA associated vasculitis may
| Table 1 | Reported cases of genuine vasculitis in SARS-CoV-2 infection |
|---------|-------------------------------------------------------------|
|         | **N.of cases** | **Gender** | **Age** | **Underlying conditions** | **Symptoms** | **Workup** | **Timing** | **Treatment** | **Outcome** |
| Cutaneous: CSVV/LCKV [69–75] / UV [76–82] | 6 CSVV/LCKV: 7 X M 1.5–83 | Only in three patients: 1. HTN, TIA, AF, CKD 2. HTN, DM 3. HTN, MI, HF, COPD | CSVV/LCKV: chilblain-like, ulcerative lesions; arthralgia; constitutional symptoms | Clinical; Neutrophilia; Lymphopenia; anemia hypoalbuminemia with albuminuria; C3-; LDH+CRP+ESR++; Cr++; auto immune serology++; SARS-Cov-2 serology; skin biopsy; immunolabelled SARS-Cov-2 antigens in skin biopsies; chest CT scans/ HRCT | 5 days-3 weeks after COVID-19 symptoms onset; sometimes, COVID-19 diagnosed after vasculitis onset | CSVV: Paracetamol; steroids UV: Antihistamines, steroids, Colchicine, HCQ, heparin if needed |
| UV: 9 | 8 XF | One pregnant (a case of UV) | CSVV/LCKV: chilblain-like, ulcerative lesions; arthralgia; constitutional symptoms | UV: Urticarial rash; pruritic rash; constitutional symptoms; arthralgia; abdominal tenderness; conjunctival erythema with periorbital edema; acral nonpitting edema; diarrhea; hypotension | | | |
| | | | | | | | | |
| ANCA-associated vasculitis [83–87] | 6 | 2XF 25–64 | Only in Two patients: 1. DM 2. DM and scleroderma | Fever, respiratory symptoms; GI symptoms | Clinical; ANCA+ (MPO in 3 cases, PR3 in 3 cases); Cr++; Proteinuria; Haematuria; Skin Biopsy; Renal biopsy; Chest CT scan | Simultaneously or shortly after COVID-19 diagnosis | Glucocorticoids; CYC; PEX; HCQ; rituximab, if needed | Improvement / Resolution Some with end organ damage |
| | 4XM | | | | | | | |
| IgAV/HSP [88–90] | 16 | 13XM 25–64 | HTN; Alcohol consumption; HyperL; aortic Stenosis; bladder cancer; Hirschprung disease; Ciohn disease; none or not reported in 10 cases | Fever; rhinorrhea, cough; chills; dyspnea; myalgia; fatigue; headache; pruritic rash; maculopapular rash; arthralgia or arthritis; GI symptoms (non-bloody diarrhea, hematochezia, vomiting); lower limbs pitting edema; HTN | Clinical; CRP++; ESR++; C3-; leucocytosis; Anaemia; thrombocytosis or thrombocytopения; albumin-; proteinuria; haematuria; Cr++; hyaline casts; renal biopsy and electron microscopy; skin biopsy; IF | Simultaneously-37 days after COVID-19 | Steroids; ABX; anticoagulation; antivirals; NSAIDS; statins; Rituximab, antihelminthics | One patient died |
| | 3XF | | | | | | | |
| LVV/GCA [91, 92] | 2 | 2XM 47–50 | None | Headache; temporal thickening; paracentral acute middle maculopathy in one case | Clinical; Doppler ultrasound of the right temporal artery; FDG PET-CT scan | Simultaneously (one case); 2 months after COVID-19 | N/A in one case; Steroids in the second case | Full resolution |
be challenging in the context of severe COVID-19 infection due to shared anatomical territories of infection and inflammation. Also, the multisystem nature of severe COVID-19 infection and the fact that a multiplicity of autoantibodies, including anti-neutrophil cytoplasmic antibodies (ANCA) may appear during infection may complicate the diagnosis [96]. One potential mechanism for ANCA development and other autoantibody development in general in the context of COVID-19 infection is the presence of extensive neutrophil infiltration and neutrophil extracellular traps (NETs) at sites of immunothrombosis and tissue necrosis that could contribute to tissue tolerance failure with antibodies formation [96–98]. In one report about the prevalence of ANCA in hospitalized COVID-19 patients, 57% of randomly selected patients sera confirmed positive for ANCAs, of which 72% were C-ANCA, and 28% were P-ANCA, but only one sample was myeloperoxidase positive [99]. In the same report, there was a positive association between C-ANCA status with intensive care unit admission but not death. Whether these ANCA autoantibodies play a true role in the pathogenesis and severity of COVID-19 still need to be determined. Also, a plethora of other antibodies have been reported in severe COVID-19 and may reflect tissue tolerance breakdown or occasionally perhaps play a role in pathology [100, 101].

Allowing for these caveats, to the best of our knowledge, there are only six described cases of ANCA associated vasculitis with temporal association with COVID-19 infection; most patients were previously healthy, two females and four males, with an age range from 25 until 64 years. All described cases were ANCA positive, and the diagnosis made simultaneously or shortly after the COVID-19 diagnosis. All patients survived after treatment with immunosuppressive medications with some accruing irreversible end organ damage [83–87].

Immunoglobulin A Vasculitis (IgAV)/Henoch-Schönlein Purpura IgAV is typically a childhood and early adolescent disease and is linked strongly to triggering environmental factors with subsequent immune-complex deposition and complement activation [102]. Sixteen cases of IgAV were described in correlation with COVID-19 infections, some of the cases presented simultaneously with COVID-19, but others appeared more than one month after the infection, the majority were males, and the age range was between 1 to 78 years. A high percentage of the patients suffered from purpuric rash and gastrointestinal symptoms. In some cases, the diagnosis was confirmed by skin or renal biopsy; skin biopsies revealed the classical finding of leukocytoclastic vasculitis, but some lacked positive IgA staining [89]. A Kidney biopsy was reported in six patients, all kidney biopsies were positive for IgA on direct immunofluorescence staining, usually in the context of a mesangial proliferative
pathology [88–90]. Electron microscopy showed mesangial and subendothelial immune deposits to podocyte effacement in IgAV [88–90].

**Goodpasture's syndrome** Given that the alveolus and the endothelium are prominent targets in severe COVID-19, then a genuine concern exists that severe SARS-CoV-2 infection with pulmonary basement membrane damage could lead to tolerance failure and the development of autoimmunity (Fig. 3). Indeed, autoimmunity to a plethora of antigens including cytokines and endothelial molecules and others are well reported in severe or critical COVID-19 [103, 104]. An interesting case report supplemented by epidemiological data trends in the London region of the UK showed cases of Goodpasture's syndrome increasing following COVID-19 [93]. Thankfully, Goodpasture's syndrome cases in the literature have totalled only nine cases, and it is interesting why this is comparatively underrepresented given the target tissue and the multiplicity of other reported autoantibodies.

**The SARS-CoV-2 Virus Bespoke Vasculitides**

Although not included in our systemic literature review, “COVID toes” and KD like vasculitis were the most frequently reported vasculitides with COVID-19 infection and discussed separately below. Otherwise, healthy people presented during the first phase of the COVID-19 outbreak without respiratory symptoms and SARS-CoV-2 PCR test negativity but with chilblain lesions, of erythema or dusky discolouration of the digits in particular [105–107]. Histological evaluation of these lesions confirmed a small vessel vasculitis with lymphocytic infiltration and interferon pathway activation within tissue as evidenced by MX-1 staining [108] suggesting a interferonopathy disease mechanism akin to monogenic systemic lupus erythematosus variants as first defined by Crow et al. [109, 110]. These lesions were identical to the typical chilblain pattern of autoimmune chilblain lesions exhibiting both a similar pattern of lymphocytic infiltration and interferon staining [111, 112].

---

**Fig. 3** COVID-19 infection triggering Goodpasture’s syndrome. SARS-CoV-2 infection triggers profound inflammatory response and basement membrane damage, leading to tolerance failure, which may lead to the production of anti-basement membrane antibodies, eventually resulting in Goodpasture’s syndrome.
A severe inflammatory reaction termed MIS has been reported in children and encompasses cardiac aneurysmal involvement [113–116], and it seems to be the most common reported vasculitis syndrome after SARS-CoV-2 infection with estimated incidence of 316 person per 1,000,000 SARS-CoV-2 infection in person younger than 21 years and most closely resembles KD [117, 118]. Prior to the emergence of SARS-CoV-2 this vasculitic pathology was a typical feature of KD in children under five of age but the emergent SARS-CoV-2 related pathology affects older children who develop MIS [119, 120]. Unlike COVID-19 pneumonia, young subjects who develop MIS may be a PCR negative for SARS-CoV-2 but usually antibody positive [113, 118, 120–122], suggesting some sort of immune hypersensitivity reaction to SARS-CoV-2. Beyond the KD-like vasculitis, patients may also experience prominent abdominal symptoms [121] and different mechanisms have been advocated to explain this genuine vasculitis related pathology. Given that KD itself is poorly understood, it remains unclear how KD like disease develops with different theories including potentially a superantigen mediated disease related to persistent spike protein antigen [123].

SARS-CoV-2 Vaccination Reports of Vasculitis.

There is a well-recognized association between natural infection or vaccination and the occasional precipitation or activation of either autoinflammatory or autoimmune diseases, but causality is not certain. Given the known role of spike protein potentially downregulating ACE in experimental settings then a theoretical concern exists around spike protein-based coronavirus vaccines and vasculitis pathology [20, 124]. This is mitigated against by very low level of systemic protein expression with vaccines based on RNA backbones [125]. A few well documented rare immune reactions have been described following SARS-CoV-2 vaccination, most notably vaccine-induced immune thrombocytic thrombocytopenia (VTIT) after DNA vaccination and myocarditis following RNA vaccination [126–130]. Furthermore, spike protein-based vaccines permit investigation of whether a specific viral component, namely spike protein, might be linked to recognized immunopathology such as KD like disease or other vasculitis.

As of September 2021, there were fifty cases [131–151] of reported vasculitis with temporal association with COVID-19 vaccination. Of these cases, only twenty-three peer-reviewed cases are newly diagnosed vasculitis (Table 2) [131–147]. Cutaneous vasculitides were the most common type of reported vasculitis, with a total of ten patients described in the literature [131–138], and noting that we excluded “COVID toes” from our search these included cutaneous small-vessel vasculitis, leukocytoclastic vasculitis and urticarial vasculitis. This was followed by ANCA associated vasculitis with total of five patients [139–142, 144] and then with IgA vasculitis or HSP with four reported cases [143–146]. Eight cases had underlying comorbidities. Only three of these cases had prior SARS-CoV-2 infection. Symptom onset occurred from a few hours to four weeks after COVID-19 vaccination, all patients had a good outcome, and full recovery was generally reported.

Despite anecdotal reports of COVID-19 vaccine-induced MIS, larger cohorts have not confirmed as association. In one report of 20 patients with MIS, seven reported to have MIS after COVID-19 vaccination; all patients had evidence of previous COVID-19 infection, so COVID-19 induced MIS was not ruled out in these cases [152]. In another report of 107 pediatric patients admitted to intensive care units in France within two months period because of MIS, 33 of them were eligible for vaccination but none were fully vaccinated, and only 7 received one dose [135, 153]. It remains uncertain whether spike protein vaccines alone can trigger MIS, thus incriminating this antigen that MIS.

The cutaneous “COVID toes” has been reported in temporal association with COVID-19 vaccination, which likely reflects poorly understood excessive type 1 interferon response to spike protein encoding nucleic acid and is reminiscent of SARS-CoV-2 where replicating virus is not usually detectable in COVID toes [154, 155].

As stated earlier, Goodpasture syndrome was associated with the COVID-19 pandemic [93] With respect to relevant vaccination, only two cases of questionable anti-GBM nephritis without pulmonary involvement were reported. In the first case, anti-GBM antibodies were negative, and the diagnosis was suspected based on histology [156]. In the putative second case anti-GBM nephritis was accompanied by mesangial IgA deposit [157]. In some way, this difference in Goodpasture frequency may be explained by the absence of tissue damage after the COVID-19 vaccination as opposed to SARS-CoV-2 infection in which basement membrane damage provokes the production of anti-basement membrane antibodies but case numbers are too small to be definitive (Fig. 3).

Potential COVID Vasculitis Mimic Related to Small Vessel Thrombosis

As distinct from the vasculitis occurring in mild COVID-19 disease that is IFN associated, a second clinical pattern of cutaneous vasculitis has been reported in severe or critical COVID-19. It is possible that some of the aforementioned diagnosed vasculitides may in fact fall within the vasculitis mimic category, that is linked to primary immunothrombotic mechanisms. Retiform purpura, livedo reticularis and
Table 2: Reported cases of genuine vasculitis after COVID-19 vaccination

| Type of Vasculitis | N.of cases | Gender | Age | Underlying conditions | Symptoms | Workup | Type of vaccine | Treatment |
|--------------------|------------|--------|-----|-----------------------|----------|--------|----------------|-----------|
| Cutaneous: CSVV 131-134 | 4 | 3 M | 31-83 | Only in two patients: 1. HTN; HyperL.; mechanical AVR (on warfarin); Algy to ibuprofen (mild rash) 2. HTN; Hypothyroidism | CSVV: Purpuric rash; fever; Itchy maculo-papular rash; Pitting oedema LKCV: Purpura UV: Urticarial rash; fever; arthralgia | Clinical; CRP + ESR +; auto immune serology +; skin biopsy | 1 X Jan 1 X Oxf 3X Pli | CSVV: Systemic or topical steroids / anti Histamine LKCV: NA in two cases. UV: Oral indomethacin, topical calamine lotion, levcetirizine Antihistamines, steroids, dapsone |
| ANCA-associated vasculitis 139-142, 144 | 5 | 2 FX 3 XM | 37-81 | Only in two patients: 1. Graves' disease 2. T2DM; HTN; PAF | Flu-like; Anorexia; Rash; fever; pain; Haemoptysis; GI symptoms | Clinical; ANCA +; CRP +; Cr +; Proteinuria; Haematuria; Skin Biopsy Renal biopsy (in two cases); Chest CT scan; [18F]FDG-PET/CT (increased uptake in medium-sized vessels) | 2X Pli 2X Oxf 1X Mod | Sys steroids, oral CYC/ Rituximab/plasmapheresis if needed |
| IgAV 143, 144/ HSP 145, 146 | IgAV: 2 | IgAV: 2XM | 39-72 | HTN; MI; T2DM; obesity; Asthma; Osteosarcoma; Intercostal shingles; tonsillectomy Hashimoto's thyroiditis; Assisted reproductive therapy | Flu-like illness; Purpura; Arthralgia; Fever; macroscopic haematuria | IgAV: Clinical; CRP +; Cr +; Skin biopsy one case; Renal biopsy one case; HSP: Clinical; CRP +; ANA +, RF +; Microscopic haematuria | 2X Oxf 1X Mod 1X Pli | IgAV: Sys steroids, CYC when needed HSP: Sys steroids |
| Vasculitis NOS 135 | 3 | N/A | N/A | N/A | N/A | N/A | N/A | 2x Mod 1x Pli | N/A |
| LVV [147] | 1 | F | 78 | None | Cephalalgia, Osteomyalgia | [18F] FDG-PET/ CT+(large arteries of the legs); CRP+, ESR+ | Mod | N/A |

Abbreviation: CSVV- Cutaneous small-vessel vasculitis, LKCV- Leukocytoclastic vasculitis, UV- Urticarial vasculitis, IgAV- IgA Vasculitis, HSP- Henoch-Schönlein Purpura, ANCA - Anti-neutrophil cytoplasmic antibodies, LVV - Large vessel vasculitis, + - positive/elevated, F- Female, M- Male, HTN- Hypertension, HyperL- Hyperlipidemia, AVR- Aortic valve replacement, Algy - Allergy, Mod - Moderna COVID-19 vaccine (mRNA-1273), Jan- Janssen Ad26.COV2.S, Oxf- Oxford-AstraZeneca, Pfi- BNT162B2/Pfizer, Sys- systemic, PAF- paroxysmal atrial fibrillation, T2DM- Type 2 Diabetes mellitus, GI- gastro-intestinal, Cr- Creatinine, RF- rheumatoid factor, CT- computer tomography, CYC- cyclophosphamide, ABX- Antibiotics, N/A- not available, NOS- not otherwise specified
purpuric lesions have a quite distinct immunopathology and are characterized by vessel lumen thrombosis and pauci-immune infiltration and an absence of IFN pathway protein expression in the tissue[105, 108, 158, 159].

Akin to lung pathology in COVID-19 pneumonia, there is a lack of evidence for direct endothelial infection. However, immunochemistry has shown staining for SARS-CoV-2 related proteins in the vascular lumen[32, 159–161]. It has been suggested that such pulmonary shedding of SARS-CoV-2 non-replicating viral fragments or “pseudo-virus” (spike, envelope, membrane proteins with or without viral RNA) may lead to ACE-2 engagement with resultant endothelial disturbance triggering local inflammation and then the wider thrombotic and vasculitic pathology[162]. It has also emerged that viral protein antigenaemia is strongly linked to systemic inflammatory responses and severity of COVID-19 pneumonia. These pauci immune lesions have been associated with complement C5-9 terminal pathway activation. Whether complement is playing a role driver role in such thrombotic immunopathology is unclear as vascular ischemia damage may also activate the complement system[40, 159, 163–166].

We have proposed two simple mechanism for this vasculitis mimic immunopathology[167]. First, physiological immunothrombosis contains the SARS-CoV-2 virus in the pulmonary territory but breakdown of the alveolar-vascular barrier with translocation of viral RNA and debris to the systemic circulation including small arteriolar, capillary, and venous circulation is associated with RNAemia activation of immunothrombosis at sites distant from the lungs (Fig. 4). Given that the extensive pulmonary immunothrombosis is also evident in the pulmonary venular territory in postmortem studies and occasionally thrombosis in the pulmonary vein root on computed tomography pulmonary angiogram studies, we proposed that embolization from this territory distal to the alveolar-capillary clot filtration system offered a novel hitherto unappreciated source of embolization[168, 169]. Further detailed postmortem pathological studies of lung tissue and distal organs are needed to confirm this theory.

Critical COVID-19 pneumonia is associated with organ ischemia in many territories including the brain where cryptogenic strokes are commonly reported[170, 171]. Some of these ischemic complications, especially pulmonary embolism and venous thrombosis are much commoner with COVID-19 compared to influenza A pneumonia and likely reflects the differential alveolar versus bronchial tissue tropism[172–174]. These lesions do not show typical histological features of vasculitis and are pauci immune. Hae-maturia is reported in over 40% of cases with renal involvement in severe COVID-19 pneumonia but histologically the changes are of ischaemic injury rather than vasculitis[175, 176]. Likewise, intestinal ischemia is a common manifestation and histology shows diffuse ischemic change rather than vasculitis[177]

**Conclusions**

The massive alveolar-capillary territory juxtaposition forms the key insight to understanding the physiological role of vascular immunity in containing infection within the alveolar space. This is associated with extensive non-infectious endotheliitis or endothelialopathy that appears to be predominantly cytokine and inflammatory mediator driven and dysregulation of this pathway leads to local and systemic immunothrombosis that serves as a vasculitis mimic. Despite the initial obvious link with the ACE2 receptor, it appears that the vasculitis mimic mechanism is not strongly linked to this. Occasional vasculitis does occur with COVID-19 and with the exception of the rare MIS pathology the vasculitis is usually self-limiting and furthermore both KD like vasculitis and “COVID toes” do not appear to be linked to productive viral infection in...
airways or the lungs. Mechanistically, COVID toes have been best conceptualized in relationship to excessive interferon driven response in the skin with strong similarities to the monogenic type 1 interferonopathies that caused chilblain lupus[108]. MIS exhibits features of KD in some patients including coronary vasculitis, but the mechanism remains unclear as KD itself is not well understood. There is no evidence that SARS-CoV-2 vaccine strategies, many of which encode for spike protein, have contributed to the bone fide vasculitis pathology apart from occasional reports of “COVID toes” following vaccination. Overall, the COVID-19 pandemic has served a highly informative model for a refined understanding of vascular immunopathology mechanism following the global emergence of a novel RNA virus.

Declarations

Ethics declarations Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals.
Not applicable.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fox SE et al (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8(7):681–686
2. Milross L et al (2022) Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. Lancet Respir Med 10(1):95–106
3. Zhang H et al (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46(4):586–590
4. Hamming I et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–7
5. Hoffmann M et al (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271-280.e8
6. Crackower MA et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417(6891):822–828
7. Zhong J et al (2010) Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation 122(7):717–728
8. Ziegler CG et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016-1035e19
9. Nicin L et al (2020) Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J 41(19):1804–1806
10. Jia H, Yue X, Lazartigues E (2020) ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. Nat Commun 11(1):5165
11. Oudit GY et al (2003) The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13(3):93–101
12. Kragstrup TW et al (2021) Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. PLOS ONE 16(6):e0252799
13. Rivellese F, Prediletto E (2020) ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev 19(6):102536–102536
14. Tignanelli CJ et al (2020) Antihypertensive drugs and risk of COVID-19? Lancet Respir Med 8(5):e30–e31
15. Semenzato L et al (2021) Antihypertensive Drugs and COVID-19 Risk. Hypertension 77(3):833–842
16. Moore N et al (2021) NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Saf 44(9):929–938
17. Oudit G et al (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 39(7):618–625
18. Chong PY et al (2004) Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 128(2):195–204
19. Nicholls JM et al (2003) Lung pathology of fatal severe acute respiratory syndrome. The Lancet 361(9317):1773–1778
20. Kuba K et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 11(8):875–879
21. Nuovo GJ et al (2021) Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol 51:151682–151682
22. Arabi YM et al (2017) Middle East Respiratory Syndrome. N Engl J Med 367(6):584–594
23. Memish ZA et al (2020) Middle East respiratory syndrome. The Lancet 395(10229):1063–1077
24. Giannis D, Ziogas IA, Gianni P (2020) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 127:104362
25. Wang N et al (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23(8):986–993
26. Nicosia RF et al (2021) COVID-19 vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. Am J Pathol 191(8):1374–1384
27. McCracken IR et al (2021) Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection
by SARS-CoV-2 in human endothelial cells. Circulation 143(8):865–868
28. Zhao Y et al (2020) Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med 202(5):756–759
29. Ackermann M et al (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 383(2):120–128
30. Polak SB, et al (2020) A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 33(11):2128–2138
31. Bussani R, et al (2020) Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine 61
32. Varga Z et al (2020) Endothelial cell infection and endothelitis in COVID-19. Lancet 395(10234):1417–1418
33. Goldsmith CS et al (2020) Electron microscopy of SARS-CoV-2: a challenging task. The Lancet 395(10238):e99
34. Schimmel L et al (2021) Endothelial cells are not productively infected by SARS-CoV-2. Clinical & translational immunology 10(10):e1350
35. Nicholls JM et al (2006) Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Medicine 3(2):e27
36. To K, Lo AW (2004) Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 203(3):740–743
37. Dorward DA et al (2021) Tissue-Specific Immunopathology in Fatal COVID-19. Am J Respir Crit Care Med 203(2):192–201
38. Carveli J et al (2020) Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 588(7836):146–150
39. Calabrese F, et al (2020) Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Archiv: an international journal of pathology 477(3):359–372
40. Loo J, Spittle DA, Newham M (2021) COVID-19, immuno-thrombosis and venous thromboembolism: biological mechanisms. Thorax 76(4):412–420
41. Land WG (2021) Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome—with a preliminary reference to SARS-CoV-2 pneumonia. Genes Immun 22(3):141–160
42. Fei Y et al (2020) Coagulation Dysfunction A Hallmark in COVID-19. Arch Pathol Lab Med 144(10):1223–1229
43. Englert H, et al (2021) Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine 67
44. Wang J et al (2021) SARS-CoV-2 infection induces the activation of tissue factor–mediated coagulation via activation of acid sphingomyelinase. Blood 138(4):344–349
45. McGonagle D et al (2020) Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. The Lancet Rheumatology 2(7):e437–e445
46. McGonagle D, Bridgewood C, Meaney JF (2021) A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19. Lancet Respir Med 9(6):665–672
47. Goshua G et al (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 7(8):e575–e582
48. O’Sullivan JM et al (2020) Endothelial cells orchestrate COVID-19 coagulopathy. The Lancet Haematology 7(8):e553–e555
49. Pagnoux C, Cohen P, Guillemin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24(2):S71
50. Lidar M et al (2009) The infectious etiology of vasculitis. Autoimmunity 42(5):432–438
51. Tiecco G et al (2021) A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. Pathogens 10(11):1364
52. Kakumani PL, Hajj-Ali RA (2009) A forgotten cause of central nervous system vasculitis. J Rheumatol 36(3):655–655
53. Lithgow KV et al (2020) Identification of the Neurinvasive Pathogen Host Target, LamR, as an Endothelial Receptor for the Treponema pallidum Adhesin Tp0751. Msphere 5(2):e00195-e220
54. Kallenberg CG (2011) Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 70(Suppl 1):i59–i63
55. Wang JJ et al (2020) Association of the infectious triggers with childhood Henoch-Schönlein purpura in Anhui province, China. J Infect Public Health 13(1):110–117
56. Belizna CC et al (2009) Infection and vasculitis. Rheumatology 48(5):475–482
57. Muñoz-Grajales C, Pineda JC (2015) Pathophysiologic relationship between infections and systemic vasculitis. Autoimmune diseases 2015
58. Dammacco F, Sansonno D (2013) Therapy for hepatitis C virus–related cryoglobulinemic vasculitis. N Engl J Med 369(11):1035–1045
59. Bonetto C et al (2016) Vasculitis as an adverse event following immunization–systematic literature review. Vaccine 34(51):6641–6651
60. Greco A et al (2018) Behçet’s disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17(6):567–575
61. Le Joncour A et al (2019) Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease. Ann Rheum Dis 78(9):1274–1282
62. Barnes BJ et al (2020) Targeting potential drivers of COVID-19: Neutrophil extracellular traps. The Journal of experimental medicine 217(6):e20200652
63. Middleton EA et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136(10):1169–1179
64. Zuo Y, et al (2020) Neutrophil extracellular traps in COVID-19. JCI insight 5(11).
65. REMAP-CAP A.-a., A, Investigators (2021) Therapeutic anti-coagulation with heparin in critically ill patients with Covid-19. N Engl J Med 385(9):777–789
66. Group RC (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693–704
67. Yurttaş B et al (2020) Characteristics and outcomes of Behçet’s syndrome patients with Coronavirus Disease 2019: a case series of 10 patients. Intern Emerg Med 15(8):1567–1571
68. Watad A et al (2021) Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines 9(5):435
69. Kumar G et al (2021) Leucocyteoclastic vasculitis secondary to COVID-19 infection in a young child. BMJ Case Reports 14(4):e242192
70. Mayor-Ibarguren A et al (2020) Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report. J Eur Acad Dermatol Venereol 34(10):e541–e542
71. Papa A et al (2020) Images in practice: painful cutaneous vasculitis in a SARS-Cov-2 IgG-positive child. Pain Ther 9:805–807

© Springer
72. Dominguez-Santos M et al (2020) Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatol Venereol 34(10):e536–e537

73. Tahri A et al (2020) Widespread cutaneous small vessel vasculitis secondary to COVID-19 infection. Int J Dermatol 59(10):1278–1279

74. da Cruz Gouveia PA et al (2021) Exuberant bullous vasculitis associated with SARS-CoV-2 infection. IDCases 23:e01047

75. Negrii S et al (2020) An unusual case of bullous haemorrhagic vasculitis in a COVID-19 patient. J Eur Acad Dermatol Venereol 34(11):e675–e676

76. de Peraozhno Lobo D et al (2020) Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol 34(10):e566–e568

77. Shahididadar M et al (2021) SARS-CoV-2 infection as a potential triggering factor for urticarial vasculitis during pregnancy: A case report. Clinical Case Reports 9(6):e04323

78. Mohta A, Mehta RD, Ghiya BC (2021) Multisystem Inflammatory Syndrome in Children Related to COVID-19 With Urticarial Vasculitis—A Double Whammy? Indian Pediatrics 58(9):894

79. Najafzadeh M et al (2020) Urticaria (angioidema) and COVID-19 infection. J Eur Acad Dermatol Venereol 34(10):e568–e570

80. Nasiri S et al (2020) Urticarial vasculitis in a COVID-19 recovered patient. Int J Dermatol 59(10):1285–1286

81. Criado PR et al (2021) Urticarial vasculitis revealing immuno-labelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg? J Eur Acad Dermatol Venereol 35(9):e563–e566

82. Hope L, et al (2021) The COVID rash that puts the ‘U’in GROUCH! in Baylor University Medical Center Proceedings Taylor & Francis

83. Duran TI, et al (2021) ANCA-associated vasculitis after COVID-19. Rheumatol Int 1–7

84. Uppal NN et al (2020) De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney international reports 100.

85. Sharma P et al (2020) COVID-19–associated kidney injury: a case series of kidney biopsy findings. J Am Soc Nephrol 31(9):1948–1958

86. Moeinizadeh F et al (2020) Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis 14(3):239–242

87. Jalalzadeh M, et al (2021) Antineutrophil cytoplasmic antibody-associated glomerulonephritis in a case of scleroderma after recent diagnosis with COVID-19. Cureus 13(1)

88. Farooq H et al (2022) The pathogenesis of COVID-19-induced IgA nephropathy and IgA vasculitis: a systematic review. J Taitah Univers Med Sci 17(1):1–13

89. Jedlowski PM et al (2022) Coronavirus disease 2019-associated immunoglobulin A vasculitis/Henoch–Schönlein purpura: a case report and review. J Dermatol 49(1):190–196

90. Sharma P et al (2021) Pathology of COVID-19–associated acute kidney injury. Clinical kidney journal 14(Supplement 1):i30–i39

91. Riera-Martí N, Romani J, Calvet J (2021) SARS-CoV-2 infection triggering a giant cell arteritis. Medicina clinica (English ed) 156(5):253

92. Jonathan GL, Scott FM, Matthew KD (2021) A Case of Post-COVID-19–Associated Paracentral Acute Middle Maculopathy and Giant Cell Arteritis–Like Vasculitis. J Neuroophthalmol 41(3):351–355

93. Prendecik M et al (2020) Anti–glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 98(3):780

94. Nahhal S, et al (2020) Anti-glomerular basement membrane disease as a potential complication of COVID-19: a case report and review of literature. Cureus 12(12)

95. Dixon L et al (2021) Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathology. J Neurol Neurosurg Psychiatry 92(1):103–104

96. Kadkhoda K, Laurita K (2021) Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell Death Discovery 7(1):277

97. Söderberg D and Segelmark M (2016) Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol 7(256).

98. Sawadogo SA et al (2020) How NETosis could drive “Post-COVID-19 syndrome” among survivors. Immunol Lett 228:35–37

99. Kadkhoda K, Laurita K (2021) Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell death discovery 7(1):1–3

100. Wijst MGPVD et al (2021) Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Science Translational Medicine 13(612):eabh2624

101. Knight JS et al (2022) Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol. https://doi.org/10.1007/s00281-022-00916-w

102. Heineke MH et al (2017) New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev 16(12):1246–1253

103. Bastard P et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370(6515):eabd4585

104. Vlahoyiannopoulos PG et al (2020) Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis 79(12):1661–1663

105. Galván Casas C et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 183(1):71–77

106. Freeman EE et al (2020) Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol 83(2):486–492

107. Kolivras A et al (2020) Coronavirus (COVID-19) infection–induced chilblains: A case report with histopathologic findings. JAAD case reports 6(6):489–492

108. Magro C et al (2021) The skin as a critical window in unveiling the pathophysiology of COVID-19. Clin Dermatol 39(6):934–965

109. Crow YJ (2011) Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238(1):91–98

110. Crow YJ, Stetson DB (2021) The skin as a critical window in unveiling the type I interferonopathies: 10 years on. Nat Rev Immunol. https://doi.org/10.1038/s41577-021-00633-9

111. Herman A et al (2020) Evaluation of chilblains as a manifestation of the COVID-19 pandemic. JAMA Dermatol 156(9):998–1003

112. Frumpholt L et al (2021) Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol 185(6):1176–1185

113. Feldstein LR et al (2021) Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA 325(11):1074–1087

114. Riphagen S et al (2020) Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet 395(10239):1741–1743

115. Viner RM, Whittaker E (2020) Kawasaki-like disease: emerging complication during the COVID-19 pandemic. The Lancet 395(10239):1741–1743

116. Verdini L et al (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet 395(10239):1771–1778
117. Belay ED et al (2021) Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr 175(8):837–845
118. Payne AB et al (2021) Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open 4(6):e2116420–e2116420
119. Burns JC et al (2020) Kawasaki Disease: A Brief History. Pediatrics 106(2):e27–e27
120. Pouletty M et al (2020) Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 79(8):999–1006
121. Toublanc J et al (2020) Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France; prospective observational study. BMJ 369:m2094
122. Dufort EM et al (2020) Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 383(4):347–358
123. Hobbs CV et al (2020) COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes. Front Pediatr 8:593455–593455
124. Lei Y et al (2021) SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res 128(9):1323–1326
125. Ogata AF et al (2022) Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis 74(4):715–718
126. Greinacher A et al (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 384(22):2092–2101
127. Schultz NH et al (2021) Thrombosis and Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 384(22):2124–2130
128. Barca N et al (2020) Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 385(12):1078–1090
129. Mevorach D, et al (2021) Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 385(23):2140–2149
130. Witberg G et al (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132–2139
131. Berry CT et al (2021) Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2 S vaccination. JAAD Case Reports 15:11–14
132. Guzmán-Pérez L, et al (2021) Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2. J Eur Acad Dermatol Venereol 35(11):e741–e743
133. Vassallo C et al (2021) Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine. Dermatol Ther 34(5):e15076–e15076
134. Kharkar V et al (2021) Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophilic preponderance. Clin Exp Dermatol 46(8):1596–1597
135. McMahon DE et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 85(1):46–55
136. Larson V et al (2022) Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 49(1):34–41
137. Bostan E, Galusser D, Gokoz O (2021) New-onset leukocytoclastic vasculitis after COVID-19 vaccine. Int J Dermatol 60(10):1305–1306
138. Dash S et al (2021) COVID-19 vaccine-induced urticarial vasculitis. Dermatol Ther 34(5):e15093–e15093
139. Okuda S, Hirooka Y, Sugiyama M (2021) Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination. Vaccines 9(8):842
140. Villa M et al (2021) A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: causality or causality? Kidney Int 100(4):937–938
141. Shakoor MT, Birkenbach MP, Lynch M (2021) ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 78(4):611–613
142. Gillion V et al (2021) Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine. Kidney Int 100(3):706–707
143. Badier L et al (2021) IgA vasculitis in adult patient following vaccination by ChAdOx1 nCov-19. Autoimmun Rev 20(11):102951–102951
144. Anderegg MA et al (2021) De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int 100(2):474–476
145. Naitlho A et al (2021) A rare case of Henoch-Schönlein Purpura following a COVID-19 vaccine—case report. SN Compr Clin Med 3(12):2618–2621
146. Hines AM et al (2021) Henoch-Schönlein purpura presenting post COVID-19 vaccination. Vaccine 39(33):4571–4572
147. Schierz J-H, et al (2021) Vasculitis and bursitis on [(18)F] FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc? European journal of nuclear medicine and molecular imaging 1–2.
148. Conticini E et al (2021) Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report. J Med Virol 93(12):6439–6441
149. Nastro F et al (2021) Small vessel vasculitis related to vari-cella-zoster virus after Pfizer-BioNtech COVID-19 vaccine. J Eur Acad Dermatol Venereol 35(11):e745–e747
150. Cohen SR et al (2021) Leukocytoclastic vasculitis flare following the COVID-19 vaccine. Int J Dermatol 60(8):1032–1033
151. Obeid M, Fenwick C, Pantaleo G (2021) Reactivation of IgA vasculitis after COVID-19 vaccination. The Lancet Rheumatology 3(9):e617
152. Belay ED, et al (2021) Multisystem Inflammatory Syndrome in Adults After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Coronavirus Disease 2019 (COVID-19) Vaccination. Clinical Infectious Diseases
153. Levy M et al (2021) Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA 327(3):281–283
154. Piccolo V et al (2021) BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. J Eur Acad Dermatol Venereol 35(8):e493–e494
155. Lopez S et al (2021) Pernio after COVID-19 vaccination. Br J Dermatol 185(2):445–447
156. Tan HZ et al (2021) Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 100(2):469–471
157. Sacker A, Kung V, Andeen N (2021) Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination. Kidney Int 100(2):471–472
158. Magro C et al (2021) The differing pathophysiology that underlie COVID-19-associated perniosis and thrombotic retinopathy: a case series. Br J Dermatol 184(1):141–150
159. Magro C et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13
160. Becker RC (2020) COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis 50(3):499–511
161. Liu F et al (2021) SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro. Front Cell Infect Microbiol 11:701278–701278
162. Magro CM et al (2021) Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol 50:151645–151645
163. Conway EM, Pryzial ELG (2020) Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost 18(11):2812–2822
164. Song W-C, FitzGerald GA (2020) COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Investig 130(8):3950–3953
165. Gorsuch WB et al (2012) The complement system in ischemia-reperfusion injuries. Immunobiology 217(11):1026–1033
166. Stahl GL et al (2003) Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162(2):449–455
167. McGonagle D et al (2021) COVID-19 vasculitis and novel vasculitis mimics. The Lancet Rheumatology 3(3):e224–e233
168. van Dam LF et al (2020) Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease? Thromb Res 193:86–89
169. Goette A et al (2020) COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation. TH open: companion journal to thrombosis and haemostasis 4(3):e271–e279
170. Zakeri A et al (2021) Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J NeuroInterv Surg 13(3):202–206
171. South K et al (2020) Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic. International journal of stroke : official journal of the International Stroke Society 15(7):722–732
172. Piroth L et al (2021) Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 9(3):251–259
173. Merkler AE et al (2020) Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol 77(11):1366–1372
174. Taquet M et al (2021) 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. The lancet Psychiatry 8(5):416–427
175. Chen T, et al (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368
176. Benedetti C, et al (2020) COVID-19 and the kidneys: an update. Front Med 7
177. El Moheb M et al (2020) Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19. JAMA 324(18):1899–1901

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.